Exelixis Inc at Bank of America Global Healthcare Conference (Virtual) Transcript
(technical difficulty) biotech analyst at Bank of America. I am pleased to be introducing our next company presenter Exelixis' CEO, Mike Morrissey. Exelixis is a commercial-stage oncology company with some interesting assets in the early-stage pipeline, so a lot to talk about. The Company is in the process of launching a new indication for CABOMETYX that's been doing, particularly, well in the marketplace. So that seems like a logical first place to start. So before we get into that, Mike, first off, thanks for joining us.
You bet. Great to be here. Thanks again for the opportunity to chat online. Looking forward to doing this live at some point in time in the near future. Before I begin, let me just remind everybody I'll be making forward-looking statements. So please see our SEC filings for a description of the risks that we face in our business.
Well, fingers crossed,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
